NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders such as depression, chronic pain, PTSD, and schizophrenia, primarily through compounds that modulate the NMDA receptor pathway in the brain. The company's core products include KETAFREE™ and NRX-100, preservative-free ketamine formulations for intravenous infusion targeting the large depression market, and NRX-101, an oral combination therapy for bipolar depression and suicidal ideation. NRx generates revenue through future pharmaceutical product sales, a clinical services subsidiary called HOPE Therapeutics that provides interventional psychiatry care including ketamine infusions, transcranial magnetic stimulation, and related treatments, and potential partnerships and licensing arrangements. The company operates through a wholly-owned subsidiary, NeuroRx, Inc., and holds a substantial global patent portfolio covering its drug candidates.